A recent study has shown that HA degradation by pegvorhyaluronidase (PVHA) can remodel the TME in a murine model of breast cancer so as to increase the uptake of anti-Programmed Death-Ligand 1 (PD-L1) therapeutic antibody. The gene discussed is CD274; the disease is breast carcinoma.